U.K. scientists cut cervical cancer death risk by 35% in major trial
Cervical cancer survival rates could improve dramatically after a major clinical trial found that adding a short course of chemotherapy before standard treatment reduces the risk of death or recurrence by 35%. Led by University College London researchers and funded by Cancer Research U.K., the trial showed 80% of women using the new approach were alive at five years, compared to 72% receiving standard treatment alone. The finding is considered the biggest advance in cervical cancer outcomes in over 20 years. Crucially, the drugs involved are already approved, widely available, and inexpensive, meaning the protocol could be adopted globally without new approvals or manufacturing delays.
